IGCS 2024 Endometrial Cancer Master Session-Part 1

Video Transcription

Video Summary

The Endometrial Cancer Master Session focused on advances and challenges in managing endometrial cancer from both a patient and medical perspective. Sarah Murphy shared her journey with Stage 1 uterine cancer and the emotional and medical challenges she faced, including deciding on a hysterectomy and exploring adoption after being unable to conceive naturally. The discussions highlighted the importance of molecular profiling in diagnosing and staging endometrial cancer, emphasizing new FIGO staging guidelines and their complexity. Pathologists and oncologists addressed challenges in implementing these guidelines globally due to resource constraints, stressing molecular profiling's role in precise treatment plans but acknowledging its current limitations in low-resource settings. Dr. Kuhn advocated for the integration of molecular staging early in the diagnosis process to improve management and prognostication. Dr. Nadeem Abu Rustam underscored the relevance of sentinel lymph node mapping in staging endometrial cancer, despite molecular advancements, to refine treatment approaches. The session also considered scenarios where molecular profiling impacts treatment decisions, such as avoiding unnecessary adjuvant therapy in high-risk patients like the P53 aberrant group. Finally, clinicians discussed the practical applications and implications of these scientific advancements in varied clinical settings, acknowledging the need for global resource-adapted guidelines.

Keywords

endometrial cancer

molecular profiling

FIGO staging guidelines

hysterectomy

sentinel lymph node mapping

adoption

resource constraints

treatment plans

adjuvant therapy

global guidelines